- Fellowship - Brown University Woman & Infant Hospital (1996), Gynecologic Pathology
- Residency - Cornell New York Presbyterian Hospital (1995), Pathology
- Fellowship - Columbia University Medical Center (1989), Molecular Reproduction
- Residency - Hospital of Obstetrics and Gynecology (1986), Obstetrics & Gynecology
- Internship - Hospital of Obstetrics and Gynecology (1983), Obstetrics & Gynecology
- Medical School - Shanghai Medical College of Fudan University (1982)
Wenxin Zheng, M.D.
- Mark and Jane Gibson Distinguished Professorship in Cancer Research
Wenxin Zheng, M.D., is a Professor with dual appointments in the Department of Pathology and the Department of Obstetrics and Gynecology at UT Southwestern Medical Center. An internationally recognized gynecologic pathologist, he specializes in all aspects of gynecologic pathology. Dr. Zheng is the Director of the Gynecologic Pathology Service and Director of the Gynecologic Pathology Fellowship at UT Southwestern.
Dr. Zheng earned his medical degree at Shanghai Medical College Fudan University. He completed a residency in obstetrics and gynecology at the Hospital of Obstetrics and Gynecology in Shanghai and, later, a residency in anatomic and clinical pathology at New York Hospital-Cornell Medical Center. He received advanced training through a gynecologic pathology fellowship at Women & Infants Hospital of Rhode Island.
Dr. Zheng also received advanced training through a postdoctoral fellowship in molecular reproduction at Columbia University College of Physicians and Surgeons.
Certified by the American Board of Pathology in combined anatomic pathology and clinical pathology, he joined the UT Southwestern faculty in 2015.
His main research contributions include endometrial serous carcinogenesis and precancerous lesion endometrial glandular dysplasia, cell origin of low-grade ovarian serous carcinoma, hormonal etiology of ovarian epithelial cancers, and tubal contribution of ovarian endometriosis and its associated ovarian cancers. In addition, he has created a novel approach called one-stop cervical care (OSCC) to diagnose and treat cervical precancers.
Dr. Zheng is a member of the United States and Canadian Academy of Pathology, the College of American Pathologists, the American Society for Colposcopy and Cervical Pathology, the Chinese Society of Colposcopy and Cervical Pathology, and the Gynecologic Oncology Group of NRG Oncology.
In 2013, he was selected by U.S. News & World Report as one of America's top pathologists.
Gynecologic and Obstetrics Pathology
Wenxin Zheng et al., (Ed.) (2013), Beijing,China, Science Press
- Gynecologic and Obstetrics Pathology
Ovarian serous carcinogenesis from tubal secretory cells.
Zhang W, Wei L, Li L, Yang B, Kong B, Yao G, Zheng W Histology and histopathology 2015 Jul 11645
Primary sources of pelvic serous cancer in patients with endometrial intraepithelial carcinoma.
Jia L, Yuan Z, Wang Y, Cragun JM, Kong B, Zheng W Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2015 Jan 28 1 118-27
Molecular identification of "latent precancers" for endometrial serous carcinoma in benign-appearing endometrium.
Zhang X, Liang SX, Jia L, Chen N, Fadare O, Schwartz PE, Kong B, Zheng W The American journal of pathology 2009 Jun 174 6 2000-6
Tubal origin of ovarian low-grade serous carcinoma.
Chen C, Li J, Yao G, Chambers SK, Zheng W American journal of clinical and experimental obstetrics and gynecology 2013 Dec 1 1 13-36
Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger.
Liang SX, Pearl M, Liang S, Xiang L, Jia L, Yang B, Fadare O, Schwartz PE, Chambers SK, Kong B, Zheng W International journal of cancer 2011 Feb 128 4 763-70
Are clear cell carcinomas of the ovary and endometrium phenotypically identical? A proteomic analysis.
Fata CR, Seeley EH, Desouki MM, Du L, Gwin K, Hanley KZ, Hecht JL, Jarboe EA, Liang SX, Parkash V, Quick CM, Zheng W, Shyr Y, Caprioli RM, Fadare O Human pathology 2015 Jun
Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis.
Li J, Fadare O, Xiang L, Kong B, Zheng W Journal of hematology & oncology 2012 5 8
Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.
Wang Y, Wang Y, Zhang Z, Park JY, Guo D, Liao H, Yi X, Zheng Y, Zhang D, Chambers SK, Zheng W Oncotarget 2016 Jan
Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis.
Wang Y, Li L, Wang Y, Tang SN, Zheng W American journal of translational research 2016 8 1 230-8
Overexpression and oncogenic function of HMGA2 in endometrial serous carcinogenesis.
Wei L, Liu X, Zhang W, Wei Y, Li Y, Zhang Q, Dong R, Kwon JS, Liu Z, Zheng W, Kong B American journal of cancer research 2016 6 2 249-59
IMP3 signatures of fallopian tube: a risk for pelvic serous cancers.
Wang Y, Wang Y, Li D, Li L, Zhang W, Yao G, Jiang Z, Zheng W Journal of hematology & oncology 2014 Jul 7 1 49
Tubal origin of ovarian endometriosis.
Yuan Z, Wang L, Wang Y, Zhang T, Li L, Cragun JM, Chambers SK, Kong B, Zheng W Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2014 Aug 27 8 1154-62
Lynch syndrome related endometrial cancer: clinical significance beyond the endometrium.
Wang Y, Wang Y, Li J, Cragun J, Hatch K, Chambers SK, Zheng W Journal of hematology & oncology 2013 Mar 6 1 22
Secretory cell expansion with aging: risk for pelvic serous carcinogenesis.
Li J, Ning Y, Abushahin N, Yuan Z, Wang Y, Wang Y, Yuan B, Cragun JM, Chambers SK, Hatch K, Kong B, Zheng W Gynecologic oncology 2013 Dec 131 3 555-60
Detection of PAX8 and p53 is beneficial in recognizing metastatic carcinomas in pelvic washings, especially in cases with suspicious cytology.
Xiang L, Zheng W, Kong B Gynecologic oncology 2012 Dec 127 3 595-600
Endometrial serous carcinoma (uterine papillary serous carcinoma): precancerous lesions and the theoretical promise of a preventive approach.
Fadare O, Zheng W American journal of cancer research 2012 2 3 335-9
A proposed model for endometrial serous carcinogenesis.
Zheng W, Xiang L, Fadare O, Kong B The American journal of surgical pathology 2011 Jan 35 1 e1-e14
Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas.
Zheng W, Fadare O International journal of clinical and experimental pathology 2012 5 3 182-6
Association between human papillomavirus type 16 E6 and E7 variants with subsequent persistent infection and recurrence of cervical high-grade squamous intraepithelial lesion after conization.
Zhang L, Yang B, Zhang A, Zhou A, Yuan J, Wang Y, Sun L, Cao H, Wang J, Zheng W Journal of medical virology 2016 Apr
Cytologic studies of the fallopian tube in patients undergoing salpingo-oophorectomy.
Chen H, Klein R, Arnold S, Chambers S, Zheng W Cancer cell international 2016 16 78
Tubal origin of ovarian endometriosis and clear cell and endometrioid carcinoma.
Wang Y, Mang M, Wang Y, Wang L, Klein R, Kong B, Zheng W American journal of cancer research 2015 5 3 869-79
Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence.
Gruessner C, Gruessner A, Glaser K, AbuShahin N, Zhou Y, Laughren C, Wright H, Pinkerton S, Yi X, Stoffer J, Azodi M, Zheng W, Chambers SK Cancer prevention research (Philadelphia, Pa.) 2014 Sep 7 9 896-905
Tubal origin of 'ovarian' low-grade serous carcinoma.
Li J, Abushahin N, Pang S, Xiang L, Chambers SK, Fadare O, Kong B, Zheng W Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2011 Nov 24 11 1488-99
High levels of Nrf2 determine chemoresistance in type II endometrial cancer.
Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W, Zhang DD Cancer research 2010 Jul 70 13 5486-96
- Ovarian serous carcinogenesis from tubal secretory cells.
- Tubal secretory cell biology
- Tubal origin of ovarian endometriosis and its related cancer development
- Ovarian cancer early detection and prevention
- Endometrial serous carcinoma: carcinogenesis, early detection and prevention
- Cervical cancer: suitable model of cervical cancer screening, effective intervention, and prevention in developing countries.
- Biomarkers to aid the diagnosis of gynecologic cancers